Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution
Abstract Objectives To analyze the treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) from a single institution. Methods From December 1989 to November 2018, 190 patients diagnosed with MMHN were included. Survival analysis was performed using the Kaplan–Meier...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Laryngoscope Investigative Otolaryngology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/lio2.1072 |
| _version_ | 1797800301811466240 |
|---|---|
| author | Shu‐Wei Chen Meng‐Hua Li Jian‐Liang Liu Jing‐Tao Chen Jia Wang Hui Li Xi‐Yuan Li Ying Zhang Ming Song Jia‐Xuan Lu Wen‐Kuan Chen |
| author_facet | Shu‐Wei Chen Meng‐Hua Li Jian‐Liang Liu Jing‐Tao Chen Jia Wang Hui Li Xi‐Yuan Li Ying Zhang Ming Song Jia‐Xuan Lu Wen‐Kuan Chen |
| author_sort | Shu‐Wei Chen |
| collection | DOAJ |
| description | Abstract Objectives To analyze the treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) from a single institution. Methods From December 1989 to November 2018, 190 patients diagnosed with MMHN were included. Survival analysis was performed using the Kaplan–Meier method for univariate analysis with a log‐rank test for significance and Cox regression for multivariate analysis. Results With a median follow‐up time of 43.5 months, 126 (68.5%) patients died. The median DSS was 35 months. The 3‐ and 5‐year disease‐specific survival (DSS) rates were 48.1% and 33.7%, respectively. The median overall survival (OS) was 34 months. The 3‐ and 5‐year OS rates were 47.0% and 32.9%, respectively. In univariate analysis, the T3 stage, received surgery, R0 resection, and combined therapy (surgery+biotherapy/biochemotherapy) were significantly associated with better survival. Multivariable Cox regression analysis revealed that the T4 stage (HR = 1.692; 95% CI, 1.175–2.438; p = .005) and the N1 stage (HR = 1.600; 95% CI, 1.023–2.504; p = .039) were strong prognostic factors for poor survival, and that combined therapy (surgery+biotherapy/biochemotherapy) was a strong prognostic factor for better survival outcome (HR = 0.563; 95% CI, 0.354–0.896; p = .015). Conclusion The prognosis of MMHN remains poor. Systemic treatment is warranted to reduce MMHN progression. Surgery combined with biotherapy may improve survival. |
| first_indexed | 2024-03-13T04:32:03Z |
| format | Article |
| id | doaj.art-823c8b22cf7b4ffebc4463ecad74a217 |
| institution | Directory Open Access Journal |
| issn | 2378-8038 |
| language | English |
| last_indexed | 2024-03-13T04:32:03Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Laryngoscope Investigative Otolaryngology |
| spelling | doaj.art-823c8b22cf7b4ffebc4463ecad74a2172023-06-19T10:16:46ZengWileyLaryngoscope Investigative Otolaryngology2378-80382023-06-018368669210.1002/lio2.1072Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institutionShu‐Wei Chen0Meng‐Hua Li1Jian‐Liang Liu2Jing‐Tao Chen3Jia Wang4Hui Li5Xi‐Yuan Li6Ying Zhang7Ming Song8Jia‐Xuan Lu9Wen‐Kuan Chen10Department of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaDepartment of Pediatric Dentistry, Guanghua School of Stomatology, Affiliated Stomatological Hospital Guangdong Provincial Key Laboratory of Stomatology, Sun Yat‐sen University Guangzhou Guangdong ChinaDepartment of Head and Neck Surgery, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou Guangdong ChinaAbstract Objectives To analyze the treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) from a single institution. Methods From December 1989 to November 2018, 190 patients diagnosed with MMHN were included. Survival analysis was performed using the Kaplan–Meier method for univariate analysis with a log‐rank test for significance and Cox regression for multivariate analysis. Results With a median follow‐up time of 43.5 months, 126 (68.5%) patients died. The median DSS was 35 months. The 3‐ and 5‐year disease‐specific survival (DSS) rates were 48.1% and 33.7%, respectively. The median overall survival (OS) was 34 months. The 3‐ and 5‐year OS rates were 47.0% and 32.9%, respectively. In univariate analysis, the T3 stage, received surgery, R0 resection, and combined therapy (surgery+biotherapy/biochemotherapy) were significantly associated with better survival. Multivariable Cox regression analysis revealed that the T4 stage (HR = 1.692; 95% CI, 1.175–2.438; p = .005) and the N1 stage (HR = 1.600; 95% CI, 1.023–2.504; p = .039) were strong prognostic factors for poor survival, and that combined therapy (surgery+biotherapy/biochemotherapy) was a strong prognostic factor for better survival outcome (HR = 0.563; 95% CI, 0.354–0.896; p = .015). Conclusion The prognosis of MMHN remains poor. Systemic treatment is warranted to reduce MMHN progression. Surgery combined with biotherapy may improve survival.https://doi.org/10.1002/lio2.1072biotherapyhead and neckmucosal melanomaprognosissurvivaltreatment |
| spellingShingle | Shu‐Wei Chen Meng‐Hua Li Jian‐Liang Liu Jing‐Tao Chen Jia Wang Hui Li Xi‐Yuan Li Ying Zhang Ming Song Jia‐Xuan Lu Wen‐Kuan Chen Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution Laryngoscope Investigative Otolaryngology biotherapy head and neck mucosal melanoma prognosis survival treatment |
| title | Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution |
| title_full | Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution |
| title_fullStr | Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution |
| title_full_unstemmed | Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution |
| title_short | Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution |
| title_sort | treatment outcomes of mucosal melanoma of the head and neck analysis of 190 cases from a single institution |
| topic | biotherapy head and neck mucosal melanoma prognosis survival treatment |
| url | https://doi.org/10.1002/lio2.1072 |
| work_keys_str_mv | AT shuweichen treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT menghuali treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT jianliangliu treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT jingtaochen treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT jiawang treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT huili treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT xiyuanli treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT yingzhang treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT mingsong treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT jiaxuanlu treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution AT wenkuanchen treatmentoutcomesofmucosalmelanomaoftheheadandneckanalysisof190casesfromasingleinstitution |